Table 1.
MicroRNA Binding to FENDRR | MicroRNA Target | Disease Association | Reference | |||
---|---|---|---|---|---|---|
MicroRNA | MicroRNA Binding Site on FENDRR (hg38) | Gene | Function | Disorder | FENDRR Expression | |
miR-15a-5p | Exon 4: 86,488,730–86,488,724 | TUBA1A | Suppresses cell proliferation and viability | Cervical cancer | Decreased | [39] |
miR-15b-5p | Exon 4: 86,488,743–86,488,723 | |||||
miR-18a-5p | Exon 4: 86,488,853–86,488,840 | IRF2 | Pro-apoptotic, suppressor of cell migration and proliferation | Non-small cell lung cancer | n/a | [40] |
ING4 | Growth inhibitor | Colorectal cancer | Decreased | [41] | ||
RUNX1 | Pro-apoptotic TF, suppressor of cell proliferation, invasion and migration | Prostate cancer | Decreased | [42] | ||
NOTCH2 | Pro-Endothelial–Mesenchymal Transition (EndMT), contributes to cardiac fibrosis | Hyperglycemia-induced EndMT and cardiac fibrosis | n/a | [43] | ||
miR-106b (mouse) | Mouse Fendrr exon 5 | Smad3 | Inhibits FOXF1 expression, pro-fibrotic | TAC-induced cardiac fibrosis | Increased | [44] |
miR-126 | Exon 1: 86,509,005–86,508,980 | VEGFA | Angiogenesis, apoptosis | Hypertensive intracerebral hemorrhage | Increased | [45] |
Positively regulates multidrug resistance gene MRP1 | Non-small cell lung cancer | n/a | [46] | |||
EGFL7 | Tumor angiogenesis | Hepatocellular carcinoma | n/a | [47] | ||
SOX2 | Positively regulates expression of PLAC1 | Gastric cancer | n/a | [48] | ||
miR-184 | Exon 4: 86,487,935–86,487,917 | MDR1 (ABCB1) | Drug transporter (miR-184 competes with HuR for FENDRR; FENDRR + HuR − MDR1; HuR > MDR1 | Chronic myelogenous leukemia; chemotherapy resistance | Decreased | [49] |
miR-214-3p | Exon 4: 86,488,737–86,488,725 | TET2 | DNA demethylation (loss of TET2 leads to hypermethylation of tumor suppressor RASSF1A promoter | Gastric cancer | Decreased | [50] |
PTEN | Tumor suppressor (negative regulator of Akt/PKB signaling) | n/a | [51] | |||
Six binding sites in exon 4 | n/a | n/a | Lung fibrosis | Decreased | [35] | |
miR-362-5p | Exon 4: 86,487,984–86,487,963 | NPR3 | Suppresses p38-MAPK signaling | Hepatocellular carcinoma cells | Decreased | [52] |
miR-423-5p | Exon 3: 86,490,399–86,490,388 | GADD45B | Inhibits cell proliferation and induces apoptosis | Hepatocellular carcinoma | Decreased | [53] |
miR-424 | n/a | FOXF1 | Suppressor of cell proliferation | Lung cancer | Decreased | [33] |
miR-761 | Exon 4: 86,488,737–86,488725 | n/a | Suppressor of cell motility and invasion | Non-small cell lung cancer | Decreased | [54] |
TIMP2 | Inhibitor of matrix metalloproteinases (MMPs) and cell invasion | Non-small cell lung cancer | Decreased | [55] | ||
miR-148a
miR-195 miR-196b miR-301b |
n/a | EPAS1 | FENDRR-miR-mRNA potential associations deduced based on comparative gene expression analysis of TCGA-lung adenocarcinoma datasets | Non-small cell lung cancer | Decreased | [56] |
EDNRB | ||||||
n/a | ||||||
SOX21 |